Document is current

Article History

Received: 4 February 2026

Accepted: 8 April 2026

First Online: 4 May 2026

Declarations

:

: The ethics committee of the University of Cologne approved this retrospective study of cohorts from an anonymized database (reference 24–1168-retro). The requirement to obtain informed consent was waived.

: HW, KS, JH, JW MH: nothing to disclose. AD discloses the following: Research support: Siemens Healthineers, Life Molecular Imaging, GE Healthcare, AVID Radiopharmaceuticals, Sofie, Eisai, Novartis/AAA, Ariceum Therapeutics. Speaker Honorary/Advisory Boards: Siemens Healthineers, Sanofi, GE Healthcare, Biogen, Novo Nordisk, Invicro, Novartis/AAA, Bayer Vital, Lilly, Peer View Institute for Medical Education, International Atomic Energy Agency, Swiss Rockets. Stock: Siemens Healthineers, Lantheus Holding, Lilly. Trials: Participation including PI-roles in industry-sponsored trials e.g. by Novartis Pharma. Patents: Patent for 18F-JK-PSMA- 7 (PSMA PET imaging tracer). 2-Alkoxy-6-[18F]Fluoronicotinoyl substituted Lys-C(O)-Glu derivatives as efficient probes for imaging of PSMA expressing tissues (Patent No.: EP3765097A1; Date of patent: Jan. 20, 2021). Grants: National and international grants including DFG Grants SFB 1451 C04, DR 445/9–1, Wellcome Leap. Memberships: Societies: DGN, EANM, SNMMI, RSNA, AAIC. Positions: Associate Editor The Journal of Nuclear Medicine, Chair Working Group Neuroscience, DGN, Member Radiation Protection Committee, Member Radiation protection committee, DGN.MS is a member of the Thyroid Committee and Guideline Committee of the German Society of Nuclear Medicine.

: Nothing to disclose.